Jul 13, 2024, 11:17
David Planchard: New option in the 1st line strategy for NSCLC EGFRmut patients
David Planchard, Thoracic Oncologist at Gustave Roussy, shared on LinkedIn:
“Great news, a new option in our 1st line strategy for NSCLC EGFRmut patients! To be discussed especially in our patients with brain metastases, ctDNA+ or high tumor load.”
Source: David Planchard/LinkedIn
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Oct 27, 2024, 17:45
Oct 27, 2024, 17:41
Oct 27, 2024, 17:31
Oct 27, 2024, 17:16
Oct 27, 2024, 17:11
Oct 27, 2024, 17:07
Oct 27, 2024, 16:50
Oct 27, 2024, 16:43
Oct 27, 2024, 14:33